Susan Lowther
Angel Investor
Cambridge, United Kingdom
Susan Lowther is a funding round investor in Cambridge focused on Biopharma and Education. Susan joined IXICO as Chief Financial Officer in October 2014. She is an experienced Executive Director with previous Board positions including Group Chief Financial Officer of Novacyt SA and Chief Financial Officer of Lab21 prior to its acquisition by Novacyt. Susan was Chief Financial Officer of BioWisdom until its acquisition by Instem plc andFinance Director of RiboTargets Limited until its acquisition by Vernalis plc.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Susan Lowther invests in
Stages Susan Lowther invests in
Countries Susan Lowther invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biopharma 1 (50%)
- Education 1 (50%)
- Biotechnology 1 (50%)
- Pharmaceutical 1 (50%)
Stage
- Funding Round 1 (50%)
- Post-IPO Equity 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products enabling improved treatments for diabetes care via the innovative reformulation of approved proteins and peptides.In addition toits internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science. | $6.6M / Sep 08, 2022 | ||
| Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products enabling improved treatments for diabetes care via the innovative reformulation of approved proteins and peptides.In addition toits internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science. | $7.4M / Post-IPO Equity / Aug 01, 2022 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Susan Lowther invest in?
Susan Lowther invests primarily in Biopharma, Education and Biotechnology startups, most often at Funding Round and Post-IPO Equity stage. Most of the 2 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Susan Lowther?
Public channels for Susan Lowther include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Susan Lowther last invest?
The most recent investment recorded for Susan Lowther closed in Sep 2022. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
